We are live on ! Find out more
ACM

Aisling Capital Management Portfolio holdings

AUM $476M
1-Year Est. Return 128.63%
This Fund
S&P 500
This Quarter Est. Return
+47.75%
1 Year Est. Return
+128.63%
3 Year Est. Return
+700.94%
5 Year Est. Return
+846.44%
10 Year Est. Return
–
AUM
$131M
AUM Growth
+$36.4M
Cap. Flow
+$5.11M
Cap. Flow %
3.89%
Top 10 Hldgs %
94.91%
Holding
12
New
–
Increased
3
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$3.24M
2
SYRE icon
Spyre Therapeutics
SYRE
+$2.94M
3
TECX
Tectonic Therapeutic
TECX
+$1.14M

Top Sells

Rank Stock Value
1
RCUS icon
Arcus Biosciences
RCUS
+$2.21M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EIDX
1
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$26.3M 20.07%
1,123,630
– –
TECX
2
Tectonic Therapeutic
TECX
$529M
$17.9M 13.64%
67,667
+6,250
+10% +$1.14M
OBSV
3
DELISTED
ObsEva SA Ordinary Shares
OBSV
$17.7M 13.51%
1,386,338
– –
BHVN
4
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$14.1M 10.76%
274,513
– –
MRKR icon
5
Marker Therapeutics
MRKR
$18.8M
$13.2M 10.06%
200,000
– –
SYRE icon
6
Spyre Therapeutics
SYRE
$8.54B
$9.83M 7.49%
48,836
+14,091
+41% +$2.94M
VIRX
7
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$9.23M 7.03%
217,143
+142,857
+192% +$3.24M
ZSAN
8
DELISTED
Zosano Pharma Corporation
ZSAN
$7.63M 5.81%
45,714
– –
NBRV
9
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$4.42M 3.36%
7,237
– –
RCUS icon
10
Arcus Biosciences
RCUS
$3.55B
$4.16M 3.17%
333,333
-203,180
-38% -$2.21M
ACRS icon
11
Aclaris Therapeutics
ACRS
$726M
$3.8M 2.89%
634,455
– –
VRNA
12
DELISTED
Verona Pharma
VRNA
$2.88M 2.2%
443,596
– –

Similar funds

BF
Brooklyn FI New York $476M AUM 17.97% 1-Year Est. Return
VIA
Vickerman Investment Advisors Spokane, Washington $476M AUM 12.21% 1-Year Est. Return
DE
Devon Energy Houston, Texas $476M AUM
FAM
Frontier Asset Management Sheridan, Wyoming $477M AUM 19.41% 1-Year Est. Return
BHWA
Beacon Harbor Wealth Advisors Virginia Beach, Virginia $477M AUM 49.25% 1-Year Est. Return
AL4A
Accel Leaders 4 Associates Palo Alto, California $475M AUM 391.52% 1-Year Est. Return
LEFP
Leading Edge Financial Planning Knoxville, Tennessee $475M AUM 15.22% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return

Aisling Capital Management's Q1 2019 Portfolio in Review

As of Q1 2019, Aisling Capital Management held 12 positions worth $131M, up 38% from $94.9M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Aisling Capital Management deployed $5.11M of net new capital in Q1 2019, adding to 3 existing holdings.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Arcus Biosciences, an estimated $2.21M trimmed.

  • Aisling Capital Management added most to Viracta Therapeutics, Inc. Common Stock in Q1 2019, an estimated $3.24M increase.
  • Aisling Capital Management's biggest Q1 2019 reduction was Arcus Biosciences, cutting an estimated $2.21M.
  • Aisling Capital Management's ten largest holdings make up 95% of its $131M portfolio in Q1 2019.
  • Aisling Capital Management opened 0 new positions and closed 0 in Q1 2019.
  • Aisling Capital Management's portfolio value rose 38% quarter-over-quarter to $131M.

Based on Aisling Capital Management's 13F filing for Q1 2019, filed 20 May 2019.